June 12, 2017—Medicaid may have overpaid drug manufacturer Mylan as much as $1.27 billion for the emergency allergy drug EpiPen from 2006 through 2016 because it was misclassified as a generic rather than brand-name drug, the Department of Health and Human Services Office of Inspector General told Senate Judiciary Chairman Chuck Grassley (R-Iowa) in a letter.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)